Author(s): Tong-PengXu, HuaShen, Ling-Xiang Liu, Yong-QianShu
Objective: To detect effects of plumbagin on proliferation and apoptosis in non-small cell lung cancer cell lines, and investigate the underlying mechanisms.
Materials and methods: Human non-small cell lung cancer cell lines A549, H292 and H460 were treated with various concentrations of plumbagin. Cell proliferation rates was determined using both cell counting kit-8 (CCK-8) and clonogenic assays. Apoptosis was detected by annexin V/propidium iodide double-labeled flow cytometry and TUNEL assay. The levels of reactive oxygen species (ROS) were detected by flow cytometry. Activity of NF-κB was examined by electrophoretic mobility shift assay (EMSA) and luciferase reporter assay. Western blotting was used to assess the expression of both NF-κB regulated apoptotic-related gene and activation of p65 and IκBκ.
Results: Plumbagin dose-dependently inhibited proliferation of the lung cancer cells. The IC50 values of plumbagin in A549, H292, and H460 cells were 10.3 μmol/L, 7.3 μmol/L, and 6.1 μmol/L for 12 hours, respectively. The compound concentration-dependently induced apoptosis of the three cell lines. Treatment with plumbagin increased the intracellular level of ROS, and inhibited the activation of NK-κB. In addition to inhibition of NF-κB/p65 nuclear translocation, the compound also suppressed the degradation of IκBκ. ROS scavenger NAC highly reversed the effect of plumbagin on apoptosis and inactivation of NK-κB in H460 cell line. Treatment with plumbagin also increased the activity of caspase-9 and caspase-3, downregulated the expression of Bcl-2, upregulated the expression of Bax, Bak, and CytC.
Conclusions: Plumbagin inhibits cell growth and induces apoptosis in human lung cancer cells through an NF-κB-regulated mitochondrial-mediated pathway, involving activation of ROS.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/23725135
Author(s): Takiar R, Nadayil D, Nandakumar A
Author(s): GM Cragg, DJ Newman
Author(s): Kumar S, Suresh PK, Vijayababu MR, Arunkumar A, Arunakaran J
Author(s): R Baral, Chattopadhyay U ( 2004) Neem (Azadirachtaindica) leaf mediated immune activation causes prophylactic growth inhibition of murine Ehrlich carcinoma and B16 melanoma
Author(s): Udeinya IJ,Shu EN, Quakyi I,Ajayi FO
Author(s): Othman F, Motalleb G,Peng SLT,Rahmat A, Fakurazi S, et al.
Author(s): Srivastava P, Yadav N, Lella R,Schneider A, Jones A, et al.
Author(s): Kavitha K, Priyadarsini RV, Anitha P, Ramalingam K,Sakthivel R, et al.
Author(s): Elumalai P, Gunadharini DN,Senthilkumar K, Banudevi S,Arunkumar R, et al.
Author(s): Sharma C, Andrea J, Goala P, Taher MG,Tahir AR, et al.
Author(s): Dale PS, Tamhankar CP, George D, Daftary GV ( 2001) Co-medication with hydrolytic enzymes in radiation therapy of uterine cervix: evidence of the reduction of acute side effects
Author(s): Popiela T, Kulig J, Hanisch J, Bock PR
Author(s): Hsu YL, Cho CY, Kuo PL
Author(s): Kawiak A, Zawacka-Pankau J, Lojkowska E
Author(s): Liu X, Cai W, Niu M, Chong Y, Liu H, et al.
Author(s): Santosh KS, Haruyo I, Gautam S, Ahn-Kwang-Seok, Bharat BA
Author(s): Chen CA, Chang HH, Kao CY, Tsai TH, Chen YJ
Author(s): Prashar R, Kumar A, Banerjee S,Rao AR
Author(s): Prashar R, Kumar A, Hewer A, Cole KJ, Davis W
Author(s): Aruna K,Sivaramakrishnan VM
Author(s): Aruna K, Sivaramakrishnan VM
Author(s): Ganasoundari A, Uma Devi P,Rao BS
Author(s): Leyon PV, Kuttan G
Author(s): Singh N, Singh SM, Shrivastava P
Author(s): Singh SM, Singh N, Shrivastava P
Author(s): Kuo CL, Chou CC, Yung BY
Author(s): Ali H, Dixit S
Author(s): Pahadiya S, Sharma J
Author(s): Ueda JY, Tezuka Y, Banskota AH, Le Tran Q, Tran QK, et al.
Author(s): Wang S, Zheng Z, Weng Y, Yu Y, Zhang D, et al.
Author(s): Renault JH, Nuzillard JM, Le CrouÃ©rour G, ThÃ©penier P, ZÃ¨ches-Hanrot M, et al.